1-(2-iodoethyl)adamantane | 75014-39-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: 1-(2-iodoethyl)adamantane
• 英文别名: 1-iodo-2-(adamant-1-yl)ethane
• CAS: 75014-39-0
• 化学式: C₁₂H₁₉I
• 分子量: 290.187
• InChiKey: NIVVVTFIOJWQJR-UHFFFAOYSA-N

物化性质

• 沸点：
  301.6±11.0 °C(Predicted)
• 密度：
  1.522±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(2-iodoethyl)adamantane 在 sodium hydroxide 、 四(三苯基膦)钯 、 铜 、 锌 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  2-Substituted (2SR)-2-Amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors. 1. Effects of Alkyl, Arylalkyl, and Diarylalkyl Substitution

  摘要：

  In this paper, we describe the synthesis of a series of a-substituted analogues of the potent and selective group II metabotropic glutamate receptor (mGluR) agonist (1S,1'S,2'S)-carboxy-cyclopropylglycine (2, L-CCG 1). Incorporation of a substituent on the amino acid carbon converted the agonist 2 into antagonist. Ail of the compounds were prepared and tested as a series of four isomers, i.e., two racemic diastereomers. We explored alkyl substitution, both normal and terminally branched; phenylalkyl and diphenylalkyl substitution; and a variety of aromatic and carbocyclic surrogates for phenyl. Affinity for group II mGluRs was measured using [H-3]glutamic acid (Glu) binding in rat forebrain membranes. Antagonist activity was confirmed for these compounds by measuring their ability to antagonize (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced inhibition of forskolin-stimulated cyclic-AMP in RGT cells transfected with human mGluR2 and mGluR3. We found that while alkyl substitution provided no increase in affinity relative to 2, phenylethyl and diphenylethyl substitution, as in 105 and 109, respectively, were quite beneficial, The affinity of 109 was further enhanced when the two aromatic rings were joined by an oxygen or sulfur atom to form the tricyclic xanthylmethyl and thioxanthylmethyl amino acids 113 and 114, respectively. Amino acid 113, with an IC50 of 0.10 mu M in the [H-3]Glu binding assay, was 52-fold more patent than 2, whose IC50 was 0.47 mu M.

  DOI：

  10.1021/jm970497w
• 作为产物：
  描述：

  1-金刚烷乙醇 在 咪唑 、 三苯基膦 、 碘 作用下， 以 二氯甲烷 为溶剂， 反应 31.0h， 以81%的产率得到1-(2-iodoethyl)adamantane
  参考文献：
  名称：

  Pd-Catalyzed intermolecular C–H bond arylation reactions: effect of bulkiness of carboxylate ligands

  摘要：

  一个体积庞大的羧酸，在α位上带有一个1-金刚烷甲基和两个甲基取代基，被证明可以作为Pd催化的分子间C(sp2)-H键芳基化反应中高效的羧酸配体来源。

  DOI：

  10.1039/d0cc01129k
• 作为试剂：
  描述：

  2,3,4-tri-O-acetyl-1-thio-β-L-fucopyranose 、 1-(2-iodoethyl)adamantane 、 三乙胺 在 氮 、 盐酸 、 碳酸氢钠 、 水 、 1-(2-iodoethyl)adamantane 、 甲醇 、 氯仿 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以to give 2-(1-adamantyl)ethyl 2,3,4-tri-O-acetyl-1-thio-β-L-fucopyranoside (1.8 g, 66%), [α]D +18° (c, 1.5, chloroform)的产率得到2-(1-adamantyl)ethyl 2,3,4-tri-O-acetyl-1-thio-β-L-fucopyranoside
  参考文献：
  名称：

  Immunologic adjuvant thio glycoside compounds and compositions

  摘要：

  公式为Y--R的化合物，其中Y是1-硫代-β-L-岩藻糖、1-硫代-β-D-半乳糖或1-硫代-β-乳糖，而R是2-(1-金刚烷基)乙基、3-[(对四氟苯乙基)苯基]丙基、6-(5-胆甾-3β-氧基)己-3-炔基、油酸或十六烷基，可用作疫苗中的免疫佐剂。

  公开号：

  US04259324A1

文献信息

• Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
  申请人：——

  公开号：US20030078282A1

  公开（公告）日：2003-04-24

  Novel compounds having general formula (I), and pharmaceutically and veterinarily acceptable salts thereof wherein R 1, R 2, R 3, W, Y 1, Y 2, X, n and y are as defined above and processes for their preparation and intermediate compounds prepared therein. The novel compounds are useful for having utility in the treatment. of pruritic dermatoses including allergic dermatitis and atopy in animals and humans

  具有通用公式(I)的新化合物，以及药物和兽药可接受的盐，其中R 1、R 2、R 3、W、Y 1、Y 2、X、n和y如上所述定义，以及它们的制备过程和其中制备的中间化合物。这些新化合物在治疗包括动物和人类的瘙痒性皮肤病，包括过敏性皮炎和异位症方面具有用途。
• [EN] COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME<br/>[FR] COMPOSÉS UTILES POUR STIMULER LA DÉGRADATION DES PROTÉINES ET PROCÉDÉS UTILISANT CEUX-CI
  申请人：UNIV YALE

  公开号：WO2013170147A1

  公开（公告）日：2013-11-14

  The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In one embodiment, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the invention comprises a posttranslational modified protein or intracellular protein. Compounds of the present invention may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.

  本发明包括作为目标蛋白质降解剂的化合物，其中降解与目标蛋白质的类别或其定位无关。在一种实施方式中，该发明包括一种化合物，其中蛋白质降解基团与连接剂共价结合，该化合物的ClogP等于或高于1.5。本发明中考虑的目标蛋白质包括后转录修饰蛋白质或细胞内蛋白质。本发明的化合物可用于治疗蛋白质降解是一种可行的治疗方法的疾病状态，如癌症或任何一种氧化应激疾病状态。
• Compounds Useful for Promoting Protein Degradation and Methods Using Same
  申请人：Yale University

  公开号：US20160022642A1

  公开（公告）日：2016-01-28

  The present description includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the description includes a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the description comprises an androgen receptor. Compounds of the present description may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.

  本描述包括作为目标蛋白质降解剂的化合物，其中降解与目标蛋白质的类别或其定位无关。在某些实施例中，描述包括一种化合物，其中蛋白质降解基团与连接剂共价结合，该化合物的ClogP等于或高于1.5。描述中考虑的目标蛋白质包括雄激素受体。本描述的化合物可用于治疗蛋白质降解是可行治疗方法的疾病状态，如癌症或任何一种氧化应激疾病状态。
• 3-Azabicyclo&lsqb;3.1.0&rsqb;hexane derivatives useful in therapy
  申请人：Pfizer INC

  公开号：US06313312B1

  公开（公告）日：2001-11-06

  Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.

  化合物的结构式（I），其盐及其前药，其中取代基如本文所定义，被披露为在治疗鸦片类物质介导的疾病中有用的鸦片受体结合剂。还描述了制备这类物质的方法。
• Alkyl perchlorates in the Ritter-type reaction. Synthesis of N-alkylamides
  作者：N. V. Yashin、P. O. Markov、K. N. Sedenkova、D. A. Vasilenko、Yu. K. Grishin、T. S. Kuznetsova、E. B. Averina

  DOI：10.1007/s11172-020-2858-8

  日期：2020.5

  systematically studied. The reaction has a wide scope and proceeds under extremely mild conditions without any catalysts or special activation of reagents. A structural diversity of the obtained by the Ritter-type reaction N-alkyl amides bearing small ring, double bonds, additional functional groups, aromatic and adamantane fragments, was demonstrated.

  系统地研究了高氯酸烷基酯与各种结构腈的Ritter型反应。该反应范围广，在极其温和的条件下进行，无需任何催化剂或特殊活化试剂。证明了通过 Ritter 型反应获得的 N-烷基酰胺具有小环、双键、附加官能团、芳香族和金刚烷片段的结构多样性。